XXŘ&Xxxxxx;XXX&Xxxxxx; XXXXXX (EU) č. 618/2012
ze xxx 10. čxxxxxxx 2012,
xxxx&xxxxxx;x xx xxx &xxxxxx;čxxx xřxxxůxxxxx&xxxxxx; xěxxxxx-xxxxxxxx&xxxxxx;xx xxxxxxx xěx&xxxxxx; xxř&xxxxxx;xxx&xxxxxx; Xxxxxxx&xxxxxx;xx xxxxxxxxxx x Xxxx (XX) č. 1272/2008 x xxxxxxxxxxx, xxxxčxx&xxxxxx;x&xxxxxx; x xxxxx&xxxxxx; x&xxxxxx;xxx x xxěx&xxxxxx;
(Text s x&xxxxxx;xxxxxx pro XXX)
XXXXXXX&Xxxxxx; XXXXXX,
x&xxxx;xxxxxxx na Smlouvu x&xxxx;xxxxxx&xxxxxx;x&xxxxxx; Xxxxxxx&xxxxxx; unie,
x&xxxx;xxxxxxx xx xxř&xxxxxx;xxx&xxxxxx; Xxxxxxx&xxxxxx;xx xxxxxxxxxx a Rady (ES) č.&xxxx;1272/2008 xx xxx 16.&xxxx;xxxxxxxx 2008 x&xxxx;xxxxxxxxxxx, xxxxčxx&xxxxxx;x&xxxxxx; a balení x&xxxxxx;xxx x&xxxx;xxěx&xxxxxx;, x&xxxx;xxěxě x&xxxx;xxx&xxxxxx;xx&xxxxxx; xxěxxxx 67/548/XXX x&xxxx;1999/45/XX x&xxxx;x&xxxx;xxěxě xxř&xxxxxx;xxx&xxxxxx; (ES) č.&xxxx;1907/2006 (1), a zejména na čx.&xxxx;37 xxxx. 5 xxxxxx&xxxxxx;xx xxř&xxxxxx;xxx&xxxxxx;,
vzhledem k těmto xůxxxůx:
|
(1) |
Č&xxxxxx;xx 3 xř&xxxxxx;xxxx XX xxř&xxxxxx;xxx&xxxxxx; (ES) č.&xxxx;1272/2008 xxxxxxxx xxx xxxxxxx xxxxxxxxxxxx&xxxxxx;xx xxxxxxxxxx&xxxxxx; x&xxxx;xxxxčxx&xxxxxx; xxxxxxxčx&xxxxxx;xx látek. X&xxxx;xxxxxxx 3.1 je xxxxxx xxxxxx harmonizovaných xxxxxxxxxx&xxxxxx; x&xxxx;xxxxčxx&xxxxxx; xxxxxxxčx&xxxxxx;xx x&xxxxxx;xxx xx základě xxxx&xxxxxx;xx&xxxxxx; stanovených x&xxxx;č&xxxxxx;xxxxx 2 xž 5 xř&xxxxxx;xxxx I nařízení (XX) č.&xxxx;1272/2008. V tabulce 3.2 xx xxxxxx xxxxxx xxxxxxxxxxxx&xxxxxx;xx xxxxxxxxxx&xxxxxx; a xxxxčxx&xxxxxx; xxxxxxxčx&xxxxxx;xx látek xx x&xxxxxx;xxxxě kritérií xxxxxxxx&xxxxxx;xx x&xxxx;xř&xxxxxx;xxxx XX xxěxxxxx Rady 67/548/EHS xx dne 27. června 1967 x sbližování xx&xxxxxx;xx&xxxxxx;xx x správních xřxxxxxů týkajících xx xxxxxxxxxxx, xxxxx&xxxxxx; x xxxxčxx&xxxxxx;x&xxxxxx; nebezpečných látek (2). Xxxx dva seznamy xx xxxx&xxxxxx; xxěxxx, xxx xx nich xxxx xxxxxxxx aktualizované xxxxxxxxxxx x&xxxxxx;xxx, na xxxx&xxxxxx; xx již xxxxxxxx xxxxxxxxxxxx&xxxxxx; xxxxxxxxxxx, x xxx xxxxxxxxxx x xxx&xxxxxx; harmonizované xxxxxxxxxxx. |
|
(2) |
X&xxxxxx;xxx xxx xxxxxxx&xxxxxx;x&xxxxxx; xxxxx Evropské xxxxxxxx xxx chemické x&xxxxxx;xxx (XXXX) xxxxx xxxxxxxxxx x x&xxxxxx;xxxůx xxxxxxxxxxxx&xxxxxx; xxxxxxxxxxx a xxxxčxx&xxxxxx;x&xxxxxx; x&xxxxxx;xxx, xxxx&xxxxxx; xxxx xřxxxxžxxx agentuře v xxxxxxx x článkem 37 nařízení (ES) č. 1272/2008. Xx x&xxxxxx;xxxxě xěxxxx xxxxxxxxxx x na základě xřxxxx&xxxxxx;xxx obdržených xx xxxčxx&xxxxxx;xx stran je xřxxx změnit xř&xxxxxx;xxxx XX nařízení (ES) č. 1272/2008, aby xxxx xxxxžxxx xxxxxxxxxxx xxxxxxxxxxx x xxxxčxx&xxxxxx;x&xxxxxx; xěxxxx&xxxxxx;xx x&xxxxxx;xxx. |
|
(3) |
Xxxxxxxxxxxx&xxxxxx; xxxxxxxxxxx xxxxxxxx&xxxxxx; x&xxxx;č&xxxxxx;xxx 3 xř&xxxxxx;xxxx VI xxř&xxxxxx;xxx&xxxxxx; (XX) č.&xxxx;1272/2008, xx xxěx&xxxxxx; tohoto nařízení, xx xx xxxěxx xxxž&xxxxxx;x bezprostředně, xxxxť xxxxxx&xxxxxx;řxx&xxxxxx; xxxxxxxx xxxxx xxxřxxxxxx určité xxxxx&xxxxxx; xx to, xxx xxxxx novým xxxxxxxxxx&xxxxxx;x xřxxxůxxxxx xxxxčxx&xxxxxx;x&xxxxxx; a balení x&xxxxxx;xxx a směsí x xxxxxx existující x&xxxxxx;xxxx. Xxxxxx&xxxxxx;řxx&xxxxxx; xxxxxxxx budou xxxxě xxxx xxxřxxxxxx xxčxx&xxxxxx; čxxxx&xxxxxx; období xx xx, xxx xxxxx xxxxxx xxxxxxxxxx xxx xxxxxxxxxx, které xxxx&xxxxxx;xxx&xxxxxx; x&xxxx;xxx&xxxxxx;xx harmonizovaných xxxxxxxxxx&xxxxxx; látek xxxxxxxxxxxx&xxxxxx;xx xxxx karcinogenní, xxxxxxxx&xxxxxx; xxxx xxxxxx&xxxxxx; xxx xxxxxxxxxx, xxxxxxxx&xxxxxx; 1X x&xxxx;1X (tabulka 3.1) x&xxxx;xxxxxxxx&xxxxxx; 1 a 2 (xxxxxxx 3.2) xxxx xxxx xxxxxx xxxxxx&xxxxxx; xxx xxxx&xxxxxx; organismy x&xxxx;xxžxxxx&xxxxxx; xxxxxxx xxxxxxxxx&xxxxxx; xxxř&xxxxxx;xxxx&xxxxxx; &xxxxxx;čxxxx xx xxxx&xxxxxx;x xxxxxřxx&xxxxxx;, zejména xxx povinnosti stanovené x&xxxx;čx&xxxxxx;xxx&xxxx;23 nařízení Xxxxxxx&xxxxxx;xx xxxxxxxxxx a Rady (XX) č.&xxxx;1907/2006 ze xxx 18.&xxxx;xxxxxxxx 2006 x&xxxx;xxxxxxxxxx, xxxxxxxx&xxxxxx;, xxxxxxx&xxxxxx;x&xxxxxx; a omezování xxxxxxx&xxxxxx;xx x&xxxxxx;xxx, o zřízení Xxxxxxx&xxxxxx; agentury xxx xxxxxxx&xxxxxx; x&xxxxxx;xxx, o změně xxěxxxxx 1999/45/XX a o zrušení xxř&xxxxxx;xxx&xxxxxx; Xxxx (EHS) č.&xxxx;793/93, xxř&xxxxxx;xxx&xxxxxx; Komise (XX) č. 1488/94, xxěxxxxx Xxxx 76/769/EHS x&xxxx;xxěxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/XX a 2000/21/ES (3). |
|
(4) |
X&xxxx;xxxxxxx x&xxxx;xřxxxxxx&xxxxxx;x xxxxxxxxx&xxxxxx;x xxř&xxxxxx;xxx&xxxxxx; (XX) č. 1272/2008, xxxx&xxxxxx; xxxžňxxx xžxx&xxxxxx; xxx&xxxxxx;xx xxxxxxxxx&xxxxxx; x&xxxx;xřxxxxxxxx xx x&xxxxxx;xx xxxxxxxxxxxxx, xx xěxx mít dodavatelé xxžxxxx xxxž&xxxxxx;xxx harmonizovanou xxxxxxxxxxx xxxxxxxxxx v části 3 xř&xxxxxx;xxxx XX xxř&xxxxxx;xxx&xxxxxx; (ES) č. 1272/2008, xx znění xxxxxx nařízení, a xřxxxůxxxxx označování x xxxxx&xxxxxx; odpovídajícím xxůxxxxx xx xxxxxxxxx&xxxxxx; bázi xřxx 1. prosincem 2013. |
|
(5) |
Xxxxřxx&xxxxxx; stanovená x&xxxxxx;xxx xxř&xxxxxx;xxx&xxxxxx;x xxxx v souladu xx xxxxxxxxxxx x&xxxxxx;xxxx xř&xxxxxx;xxx&xxxxxx;xx xxxxx článku 133 xxř&xxxxxx;xxx&xxxxxx; (ES) č.&xxxx;1907/2006, |
XŘXXXXX TOTO NAŘÍZENÍ:
Čx&xxxxxx;xxx&xxxx;1
Č&xxxxxx;xx 3 přílohy XX xxř&xxxxxx;xxx&xxxxxx; (XX) č.&xxxx;1272/2008 xx mění xxxxx:
|
1) |
Xxxxxxx 3.1 xx xěx&xxxxxx; takto:
|
|
2) |
Tabulka 3.2 xx xěx&xxxxxx; xxxxx:
|
Čx&xxxxxx;xxx&xxxx;2
Xxxx xxř&xxxxxx;xxx&xxxxxx; xxxxxxxx x&xxxx;xxxxxxxx dvacátým dnem xx vyhlášení x&xxxx;&Xxxxxx;řxxx&xxxxxx;x xěxxx&xxxxxx;xx Xxxxxxx&xxxxxx; xxxx.
Článek 1 se xxxžxxx xxx xxx 1. xxxxxxxx 2013.
Harmonizované xxxxxxxxxxx xxxxxxxx&xxxxxx; v části 3 xř&xxxxxx;xxxx VI xxř&xxxxxx;xxx&xxxxxx; (XX) č.&xxxx;1272/2008, xx xxěx&xxxxxx; xxxxxx xxř&xxxxxx;xxx&xxxxxx;, xxx xxxž&xxxxxx;x před 1.&xxxx;xxxxxxxxx 2013.
Xxxx xxř&xxxxxx;xxx&xxxxxx; xx x&xxxxxx;xxxx&xxxxxx; x&xxxx;xxx&xxxxxx;x xxxxxxx x&xxxx;xř&xxxxxx;xx použitelné xx x&xxxxxx;xxx čxxxxx&xxxxxx;xx xx&xxxxxx;xxxx.
V Xxxxxxx xxx 10. čxxxxxxx 2012.
Xx Xxxxxx
Xxx&xxxxxx; Xxxxxx BARROSO
předseda
(1)&xxxx;&xxxx;&Xxxxxx;ř.&xxxx;xěxx.&xxxx;X&xxxx;353, 31.12.2008, x.&xxxx;1.
(2)&xxxx;&xxxx;&Xxxxxx;ř. xěxx. 196, 16.8.1967, s. 1.
(3)&xxxx;&xxxx;&Xxxxxx;ř.&xxxx;xěxx.&xxxx;X&xxxx;136, 29.5.2007, s. 3.
XŘ&Xxxxxx;XXXX&xxxx;X
|
Xxxxxxx&xxxxxx; číslo |
Mezinárodní xxxxxxxxxxxx xxxxxxx&xxxxxx;xx x&xxxxxx;xxx |
Č&xxxxxx;xxx XX |
Č&xxxxxx;xxx XXX |
Xxxxxxxxxxx |
Xxxxčxx&xxxxxx; |
Xxxxxxxxx&xxxxxx; koncent. xxxxxx, xxxxxxxxxxčx&xxxxxx; faktory |
Pozn. | |||
|
X&xxxxxx;xx xř&xxxxxx;x x xxxxxxxx&xxxxxx; xxxxxxxčxxxxx |
X&xxxxxx;xx xxxxxxxxx&xxxxxx;xx xěx x xxxxxxxčxxxxx |
X&xxxxxx;xx x&xxxxxx;xxxxžx&xxxxxx;xx symbolů x xxxx&xxxxxx;xx&xxxxxx;xx xxxx |
X&xxxxxx;xx xxxxxxxxx&xxxxxx;xx xěx o xxxxxxxčxxxxx |
X&xxxxxx;xx xxxxň. xxxxxxxxx&xxxxxx;xx xěx o xxxxxxxčxxxxx | ||||||
|
&xxxxx;009-016-00-2 |
trisodium xxxxxxxxxxxxxxxxxxx [1] |
237-410-6 [1] |
13775-53-6 [1] |
XXXX XX 1 Xxxxx Xxx. 4 Aquatic Xxxxxxx 2 |
X372 X332 X411 |
XXX07 XXX08 XXX09 Xxx |
X372 X332 X411 |
&xxxx; |
&xxxx; |
&xxxx; |
|
xxxxxxxxx xxxxxxxxxxxxxxxxxxx (cryolite) [2] |
239-148-8 [2] |
15096-52-3 [2] | ||||||||
|
603-012-00-X |
2-xxxxxxxxxxxxx; xxxxxxxx xxxxxx xxxxxxxxx xxxxx |
203-804-1 |
110-80-5 |
Xxxx. Xxx. 3 Repr. 1X Acute Xxx. 3 Xxxxx Xxx. 4 |
X226 X360XX X331 X302 |
XXX02 XXX08 XXX06 Xxx |
X226 X360XX X331 X302 |
&xxxx; |
&xxxx; |
&xxxx; |
|
603-025-00-0 |
xxxxxxxxxxxxxxx |
203-726-8 |
109-99-9 |
Xxxx. Liq. 2 Carc. 2 Xxx Irrit. 2 XXXX XX 3 |
X225 H351 X319 X335 |
GHS02 XXX07 XXX08 Xxx |
X225 X351 X319 X335 |
XXX019 |
XXXX SE 3; X335: C ≥ 25&xxxx;% Xxx Irrit.2; X319: X &xx; 25 % |
&xxxx; |
|
613-016-00-3 |
fuberidazole (XXX); 2-(2-furyl)-1H-benzimidazole |
223-404-0 |
3878-19-1 |
Xxxx. 2 Xxxxx Xxx. 4 XXXX XX 2 Skin Xxxx. 1 Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1 |
X351 H302 X373 (xxxxx) H317 H400 X410 |
XXX07 XXX08 XXX09 Wng |
X351 X302 X373 (xxxxx) X317 X410 |
&xxxx; |
X = 1 |
&xxxx; |
|
617-001-00-2 |
xx-xxxx-xxxxx xxxxxxxx |
203-733-6 |
110-05-4 |
Xxx. Perox. X Xxxx. Xxx. 2 Xxxx. 2 |
H242 X225 X341 |
XXX02 XXX08 Xxx |
H242 X225 H341“ |
&xxxx; |
&xxxx; |
|
XŘ&Xxxxxx;XXXX&xxxx;XX
|
Xxxxxxx&xxxxxx; č&xxxxxx;xxx |
Mezinárodní xxxxxxxxxxxx xxxxxxx&xxxxxx;xx x&xxxxxx;xxx |
Č&xxxxxx;xxx XX |
Č&xxxxxx;xxx XXX |
Xxxxxxxxxxx |
Xxxxčxx&xxxxxx; |
Xxxxxxxxx&xxxxxx; xxxxxxx. xxxxxx, xxxxxxxxxxčx&xxxxxx; xxxxxxx |
Pozn. | |||
|
Kódy xř&xxxxxx;x x xxxxxxxx&xxxxxx; xxxxxxxčxxxxx |
X&xxxxxx;xx xxxxxxxxx&xxxxxx;xx xěx x xxxxxxxčxxxxx |
X&xxxxxx;xx x&xxxxxx;xxxxžx&xxxxxx;xx xxxxxxů x xxxx&xxxxxx;xx&xxxxxx;xx xxxx |
Kódy xxxxxxxxx&xxxxxx;xx xěx x xxxxxxxčxxxxx |
X&xxxxxx;xx xxxxň. standardních xěx x xxxxxxxčxxxxx | ||||||
|
&xxxxx;015-199-00-X |
xxxx[2-xxxxxx-1-xxxxxxxxxxxx)xxxxx] xxxxxxxxx |
237-159-2 |
13674-87-8 |
Xxxx. 2 |
H351 |
GSH08 Xxx |
H351 |
|
&xxxx; |
|
|
015-200-00-3 |
xxxxxx xxxxxxxxx |
244-959-5 |
22398-80-7 |
Xxxx. 1X Xxxx. 2 XXXX XX 1 |
X350 X361x X372 (plíce) |
XXX08 Dgr |
X350 H361f X372 (xx&xxxxxx;xx) |
&xxxx; |
STOT XX 1; X372: C ≥ 0,1 % Carc 1X; X350: X&xxxx;&xx;&xxxx;0,01&xxxx;% XXXX RE 2; X373: 0,01&xxxx;%&xxxx;&xx; X&xxxx;&xx;&xxxx;0,1&xxxx;% |
&xxxx; |
|
015-201-00-9 |
xxxxxxxx xxxxxxxxx |
246-677-8 |
25155-23-1 |
Xxxx. 1X |
X360X |
GHS08 Xxx |
X360X |
&xxxx; |
&xxxx; |
|
|
015-202-00-4 |
xxxx(xxxxxxxxxxx) xxxxxxxxx |
247-759-6 |
26523-78-4 |
Xxxx Xxxx. 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1 |
H317 X400 X410 |
GHS07 XXX09 Xxx |
H317 X410 |
&xxxx; |
&xxxx; |
&xxxx; |
|
015-203-00-X |
diphenyl(2,4,6-trimethylbenzoyl)phosphine xxxxx |
278-355-8 |
75980-60-8 |
Xxxx. 2 |
H361f (způsobuje xxxxxxx xxxxxx) |
XXX08 Xxx |
X361x (způsobuje xxxxxxx xxxxxx) |
|
|
&xxxx; |
|
602-109-00-4 |
Hexabromocyclododecane [1] |
247-148-4 [1] |
25637-99-4[1] |
Xxxx. 2 Xxxx. |
X361 X362 |
XXX08 Xxx |
X361 X362 |
&xxxx; |
&xxxx; |
&xxxx; |
|
1,2,5,6,9,10-xxxxxxxxxxxxxxxxxxxxxx [2] |
221-695-9[2] |
3194-55-6[2] | ||||||||
|
606-143-00-0 |
abamectin (xxxxxxxxxxx xx xxxxxxxxxx X1x xxx avermectin X1x) (ISO) [1] |
_ [1] |
71751-41-2 [1] |
Xxxx. 2 Xxxxx Xxx. 2 Xxxxx Xxx. 1 XXXX XX 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1 |
X361x X300 X330 X372 (nervový xxxx&xxxxxx;x) H400 X410 |
XXX06 GHS08 XXX09 Dgr |
X361x X300 X330 X372 (xxxxxx&xxxxxx; xxxx&xxxxxx;x) X410 |
&xxxx; |
XXXX XX 1; X372: X&xxxx;&xx;&xxxx;5&xxxx;% XXXX XX 2; X373: 0,5 % ≤ X&xxxx;&xx;&xxxx;5&xxxx;% M = 10 000 |
&xxxx; |
|
xxxxxxxxxx X1x (purity ≥ 80 %); [2] |
265-610-3 [2] |
65195-55-3 [2] | ||||||||
|
606-144-00-6 |
acequinocyl (XXX); 3-xxxxxxx-1,4-xxxxx-1,4-xxxxxxxxxxxxxxxxx-2-xx xxxxxxx |
&xxxxx; |
57960-19-7 |
Xxxx Xxxx. 1 XXXX XX 1 XXXX XX 2 Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 1 |
X317 X370 (xx&xxxxxx;xx) (xxxxxxx&xxxxxx;x&xxxxxx;) X373 (krevní xxěx) X400 X410 |
XXX07 XXX08 GHS09 Xxx |
X317 X370 (xx&xxxxxx;xx) (xxxxxxx&xxxxxx;x&xxxxxx;) X373 (krevní xxěx) X410 |
|
X&xxxx;=&xxxx;1&xxxx;000 |
&xxxx; |
|
607-698-00-1 |
4-tert-butylbenzoic xxxx |
202-696-3 |
98-73-7 |
Xxxx. 1X XXXX RE 1 Xxxxx Xxx. 4 |
X360X H372 X302 |
XXX07 XXX08 Xxx |
H360F X372 X302 |
&xxxx; |
&xxxx; |
&xxxx; |
|
612-281-00-2 |
xxxxxxxxxxxxxx xxxxx; X,X,X',X'-xxxxxxxxxxx-4,4'-xxxxxxxxxxxxxxxxxxxx |
204-961-9 |
129-73-7 |
Xxxx. 2 Muta. 2 |
H351 X341 |
XXX08 Xxx |
H351 H341 |
&xxxx; |
&xxxx; |
&xxxx; |
|
616-205-00-9 |
Xxxxxxxxxxx (XXX); 2-xxxxxx-X-(2,6-xxxxxxxxxxxxxx)-X-(1X-xxxxxxx-1-xxxxxxxx)xxxxxxxxx |
266-583-0 |
67129-08-2 |
Xxxx Sens. 1X Carc. 2 Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1 |
X317 X351 H400 H410 |
XXX07 XXX08 XXX09 Xxx |
X317 X351 H410 |
&xxxx; |
M = 100 X&xxxx;=&xxxx;100&xxxxx; |
|
XŘ&Xxxxxx;XXXX&xxxx;XXX
|
Xxxxxxx&xxxxxx; č&xxxxxx;xxx |
Mezinárodní xxxxxxxxxxxx xxxxxxx&xxxxxx;xx x&xxxxxx;xxx |
Č&xxxxxx;xxx XX |
Č&xxxxxx;xxx XXX |
Xxxxxxxxxxx |
Xxxxčxx&xxxxxx; |
Xxxxxxxxxčx&xxxxxx; xxxxxx |
Xxxx. |
|
„009-016-00-2 |
trisodium xxxxxxxxxxxxxxxxxxx [1] |
237-410-6 [1] |
13775-53-6 [1] |
Xx; X20 X; X48/23/25 X; X51-53 |
T; X X: 20-48/23/25-51/53 S: (1/2-)22-37-45-61 |
|
&xxxx; |
|
xxxxxxxxx xxxxxxxxxxxxxxxxxxx (cryolite) [2] |
239-148-8 [2] |
15096-52-3 [2] | |||||
|
603-012-00-X |
2-ethoxyethanol; xxxxxxxx glycol xxxxxxxxx xxxxx |
203-804-1 |
110-80-5 |
X10 Repr. Cat. 2; X60-61 Xx; X20/22 |
T X: 60-61-10-20/22 X: 53-45 |
&xxxx; |
X |
|
603-025-00-0 |
tetrahydrofuran |
203-726-8 |
109-99-9 |
X; X11-19 Xxxx. Xxx. 3; X40 Xx; X36/37 |
X; Xx X: 11-19-40-36/37 S: (2-)(13-)16-29-33-36-37(-46) |
Xx; X36/37: X&xxxx;&xx;&xxxx;25&xxxx;% |
&xxxx; |
|
613-016-00-3 |
fuberidazole (XXX); 2-(2-xxxxx)-1X-xxxxxxxxxxxxx |
223-404-0 |
3878-19-1 |
Xxxx. Xxx. 3; X40 Xx; X48/22 Xn; X22 Xx; X43 X; R50-53 |
Xx; X X: 40-48/22-22-43-50/53 X: (2)-22-36/37-60-61 |
X; X50-53: X&xxxx;&xx;&xxxx;25&xxxx;% X; R51-53: 2,5 % ≤ C < 25 % X52-53: 0,25&xxxx;%&xxxx;&xx;&xxxx;X&xxxx;&xx;&xxxx;2,5&xxxx;% |
&xxxx; |
|
617-001-00-2 |
xx-xxxx-xxxxx xxxxxxxx |
203-733-6 |
110-05-4 |
O; R7 F; X11 Xxxx. Xxx. 3, X68 |
X; X; Xn X: 7-11-68 X: (2-)3/7-14-16-23-36/37/39&xxxxx; |
&xxxx; |
&xxxx; |
XŘ&Xxxxxx;XXXX&xxxx;XX
|
Xxxxxxx&xxxxxx; číslo |
Mezinárodní xxxxxxxxxxxx xxxxxxx&xxxxxx;xx x&xxxxxx;xxx |
Č&xxxxxx;xxx XX |
Č&xxxxxx;xxx XXX |
Xxxxxxxxxxx |
Xxxxčxx&xxxxxx; |
Xxxxxxxxxčx&xxxxxx; xxxxxx |
Xxxx. |
|
&xxxxx;015-199-00-X |
tris[2-chloro-1-chloromethyl)ethyl] phosphate |
237-159-2 |
13674-87-8 |
Xxxx. Xxx. 3; R40 |
Xx X: 40 X: (2-)36/37 |
&xxxx; |
|
|
015-200-00-3 |
xxxxxx phosphide |
244-959-5 |
22398-80-7 |
Xxxx. Xxx. 2; X45 Repr. Xxx. 3; R62 T; X48/23 |
X X: 45–48/23–62 S: 45- 53 |
X; X48/23: X &xx;0,1% Xxxx Xxx 2; X45: C &xx; 0,01% Xx; X48/20: 0,01%≤ X &xx; 0,1% |
X |
|
015-201-00-9 |
trixylyl xxxxxxxxx |
246-677-8 |
25155-23-1 |
Xxxx. Xxx. 2; X60 |
X X: 60 X: 53-45 |
&xxxx; |
&xxxx; |
|
015-202-00-4 |
tris(nonylphenyl) xxxxxxxxx |
247-759-6 |
26523-78-4 |
Xx; R43 N; R50-53 |
Xx; X X: 43-50/53 X: 24-37-60-61 |
&xxxx; |
|
|
015-203-00-X |
xxxxxxxx(2,4,6-xxxxxxxxxxxxxxxx)xxxxxxxxx xxxxx |
278-355-8 |
75980-60-8 |
Xxxx. Xxx. 3; X62 |
Xx X: 62 X: (2)-22-36/37. |
&xxxx; |
|
|
602-109-00-4 |
Xxxxxxxxxxxxxxxxxxxxxx [1] |
247-148-4 [1] |
25637-99-4[1] |
Xxxx. Xxx.&xxxx;3; X63 X64 |
Xx X: 63-64 X: 36/37-53 |
&xxxx; |
&xxxx; |
|
1,2,5,6,9,10-xxxxxxxxxxxxxxxxxxxxxx [2] |
221-695-9[2] |
3194-55-6[2] | |||||
|
606-143-00-0 |
xxxxxxxxx (combination xx avermectin B1a xxx xxxxxxxxxx B1b) (XXX) [1] |
_ [1] |
71751-41-2 [1] |
Xxxx. Xxx.&xxxx;3; X63 T+; X26/28 X; X48/23/25 N; X50-53 |
X+; X X: 63-26/28-48/23/25-50/53 X: 28-36/37-45-60-61 |
X; X48/23: X ≥ 5% Xx; X48/20: 0,5% &xx; C &xx;5% N; X50-53: C &xx; 0,0025% X; X51-53: 0,00025% &xx; C <0,0025% X52-53: 0,000025% &xx; X&xx;0,00025% |
&xxxx; |
|
avermectin X1x (xxxxxx &xx;80%); [2] |
265-610-3 [2] |
65195-55-3 [2] | |||||
|
606-144-00-6 |
acequinocyl (XXX); 3-xxxxxxx-1,4-xxxxx-1,4-xxxxxxxxxxxxxxxxx-2-xx acetate |
&xxxxx; |
57960-19-7 |
X; X39/23 Xi; X43 X; R50-53 |
X; X R: 39/23-43-50/53, X: (2-)24-37-38-60-61 |
X; X50-53: X &xx; 0,025% X; X51-53: 0,0025% &xx; X &xx; 0,025% X52-53: 0,00025% &xx; X &xx; 0,0025% |
|
|
607-698-00-1 |
4-xxxx-xxxxxxxxxxxx xxxx |
202-696-3 |
98-73-7 |
Xxxx. Xxx. 2; R60 X; X48/23/24/25 Xx; X22 |
T X: 60-22-48/23/24/25 X: 53-45 |
&xxxx; |
X |
|
612-281-00-2 |
xxxxxxxxxxxxxx green N,N,N',N'-tetramethyl-4,4'-benzylidenedianiline |
204-961-9 |
129-73-7 |
Xxxx. Cat. 3;R40 Muta. Xxx. 3; R68 |
Xx X: 40-68 X: (2-)36/37 |
&xxxx; |
|
|
616-205-00-9 |
Metazachlor (XXX); 2-chloro-N-(2,6-dimethylphenyl)-N-(1H-pyrazol-1-ylmethyl)acetamide |
266-583-0 |
67129-08-2 |
R43 Xxxx. Xxx. 3; X40 X; X50-53 |
Xx; X X: 40-43-50/53 X: (2-)36-37-60-61 |
X; X50-53: C &xx; 0,25% X; X51-53: 0,025% &xx; C &xx; 0,25% X52-53: 0,0025% &xx; X < 0,025%&xxxxx; |
&xxxx; |